Submission Details
| 510(k) Number | K221833 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | June 23, 2022 |
| Decision Date | November 07, 2022 |
| Days to Decision | 137 days |
| Submission Type | Traditional |
| Review Panel | Cardiovascular (CV) |
| Summary | Summary PDF |
K221833 is an FDA 510(k) clearance for the HemoSphere Advanced Monitor, HemoSphere ClearSight Module, a System, Measurement, Blood-pressure, Non-invasive (Class II — Special Controls, product code DXN), submitted by Edwards Lifesciences, LLC (Irvine, US). The FDA issued a Cleared decision on November 7, 2022, 137 days after receiving the submission on June 23, 2022. This device falls under the Cardiovascular review panel. Regulated under 21 CFR 870.1130.
| 510(k) Number | K221833 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | June 23, 2022 |
| Decision Date | November 07, 2022 |
| Days to Decision | 137 days |
| Submission Type | Traditional |
| Review Panel | Cardiovascular (CV) |
| Summary | Summary PDF |
| Product Code | DXN — System, Measurement, Blood-pressure, Non-invasive |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 870.1130 |